Exon skipping restores dystrophin expression, but fails to prevent disease progression in later stage dystrophic dko mice

Gene Therapy

Volumn 21, Issue 9, 2014, Pages 785-793

  Wu, B ^a   Cloer, C ^a   Lu, P ^a   Milazi, S ^a   Shaban, M ^a   Shah, S N ^a   Marston Poe, L ^a   Moulton, H M ^b   Lu, Q L ^a  

^a CAROLINAS MEDICAL CENTER   (United States)

^b OREGON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DYSTROGLYCAN; DYSTROPHIN; MORPHOLINO OLIGONUCLEOTIDE; NEURONAL NITRIC OXIDE SYNTHASE; UTROPHIN;

AGE; ANIMAL; DRUG ADMINISTRATION; EXON; GENETICS; INTRAVENOUS DRUG ADMINISTRATION; KNOCKOUT MOUSE; METABOLISM; MOUSE; MUSCULAR DYSTROPHY, ANIMAL; PATHOLOGY; SKELETAL MUSCLE;

ADMINISTRATION, INTRAVENOUS; AGE FACTORS; ANIMALS; DRUG ADMINISTRATION SCHEDULE; DYSTROGLYCANS; DYSTROPHIN; EXONS; MICE; MICE, KNOCKOUT; MORPHOLINOS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, ANIMAL; NITRIC OXIDE SYNTHASE TYPE I; UTROPHIN;

EID: 84928340028     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2014.53     Document Type: Article

References (34)

1. Hoffman EP, Brown RH Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51: 919–928. DOI: 10.1016/0092-8674(87)90579-4
2. Konieczny P, Swiderski K, Chamberlain JS. Gene and cell-mediated therapies for muscular dystrophy. Muscle Nerve 2013; 47: 649–663. DOI: 10.1002/mus.23738
3. Sherratt TG, Vulliamy T, Dubowitz V, Sewry CA, Strong PN. Exon skipping and translation in patients with frameshift deletions in the dystrophin gene. Am J Hum Genet 1993; 53: 1007–1015.
4. Dunckley MG, Manoharan M, Villiet P, Eperon IC, Dickson G. Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum Mol Genet 1998; 7: 1083–1090. DOI: 10.1093/hmg/7.7.1083
5. Mann CJ, Honeyman K, Cheng AJ, Ly T, Lloyd F, Fletcher S et al. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci USA 2001; 98: 42–47. DOI: 10.1073/pnas.98.1.42
6. Dickson G, Hill V, Graham IR. Screening for antisense modulation of dystrophin pre-mRNA splicing. Neuromuscul Disord 2002; 12 (Suppl 1): S67–S70. DOI: 10.1016/S0960-8966(02)00085-8
7. Aartsma-Rus A, Bremmer-Bout M, Janson AA, den Dunnen JT, van Ommen GJ, van Deutekom JC. Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. Neuromuscul Disord 2002; 12 (Suppl 1): S71–S77. DOI: 10.1016/S0960-8966(02)00086-X
8. Lu QL, Mann CJ, Lou F, Bou-Gharios G, Morris GE, Xue SA et al. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med 2003; 9: 1009–1014. DOI: 10.1038/nm897
9. Lu QL, Rabinowitz A, Chen YC, Yokota T, Yin H, Alter J et al. Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 2005; 102: 198–203. DOI: 10.1073/pnas.0406700102
10. Alter J, Lou F, Rabinowitz A, Yin H, Rosenfeld J, Wilton SD et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 2006; 12: 175–177. DOI: 10.1038/nm1345
11. Abes R, Arzumanov AA, Moulton HM, Abes S, Ivanova GD, Iversen PL et al. Cell-penetrating-peptide-based delivery of oligonucleotides: an overview. Biochem Soc Trans 2007; 35: 775–779. DOI: 10.1042/BST0350775
12. Amantana A, Moulton HM, Cate ML, Reddy MT, Whitehead T, Hassinger JN et al. Pharmacokinetics, biodistribution, stability and toxicity of a cell-penetrating peptide-morpholino oligomer conjugate. Bioconjug Chem 2007; 18: 1325–1331. DOI: 10.1021/bc070060v
13. Wu B, Moulton HM, Iversen PL, Jiang J, Li J, Spurney CF et al. Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci USA 2008; 105: 14814–14819. DOI: 10.1073/pnas.0805676105
14. Jearawiriyapaisarn N, Moulton HM, Buckley B, Roberts J, Sazani P, Fucharoen S et al. Sustained dystrophin expression induced by peptide-conjugated morpholino oligomers in the muscles of mdx mice. Mol Ther 2008; 16: 1624–1629. DOI: 10.1038/mt.2008.120
15. Yin H, Moulton HM, Seow Y, Boyd C, Boutilier J, Iverson P et al. Cell-penetrating peptide-conjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet 2008; 17: 3909–3918. DOI: 10.1093/hmg/ddn293
16. Wu B, Li Y, Morcos PA, Doran TJ, Lu P, Lu QL. Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice. Mol Ther 2009; 17: 864–871. DOI: 10.1038/mt.2009.38
17. Aoki Y, Nakamura A, Yokota T, Saito T, Okazawa H, Nagata T et al. In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52–deficient mdx mouse. Mol Ther 2010; 18: 1995–2005. DOI: 10.1038/mt.2010.186
18. Wu B, Lu P, Benrashid E, Malik S, Ashar J, Doran TJ et al. Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino. Gene Therapy 2010; 17: 132–140. DOI: 10.1038/gt.2009.120
19. Yokota T, Lu QL, Partridge T, Kobayashi M, Nakamura A, Takeda S et al. Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs. Ann Neurol 2009; 65: 667–676. DOI: 10.1002/ana.21627
20. Moulton HM, Moulton JD. Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy. Biochim Biophys Acta 2010; 1798: 2296–2303. DOI: 10.1016/j.bbamem.2010.02.012
21. Aoki Y, Yokota T, Nagata T, Nakamura A, Tanihata J, Saito T et al. Bodywide skipping of exons 45–55 in dystrophic mdx52 mice by systemic antisense delivery. Proc Natl Acad Sci USA 2012; 109: 13763–13768. DOI: 10.1073/pnas.1204638109
22. Wu B, Xiao B, Cloer C, Shaban M, Sali A, Lu P et al. One-year treatment of morpholino antisense oligomer improves skeletal and cardiac muscle functions in dystrophic mdx mice. Mol Ther 2011; 19: 576–583. DOI: 10.1038/mt.2010.288
23. Wu B, Lu P, Cloer C, Shaban M, Grewal S, Milazi S et al. Long-term rescue of dystrophin expression and improvement in muscle pathology and function in dystrophic mdx mice by peptide-conjugated morpholino. Am J Pathol 2012; 181: 392–400. DOI: 10.1016/j.ajpath.2012.04.006
24. van Deutekom JC, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M et al. Local dystrophin restoration with antisense oligonucleotide PRO051. N Engl J Med 2007; 357: 2677–2686. DOI: 10.1056/NEJMoa073108
25. Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, Adkin C et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 2009; 8: 918–928. DOI: 10.1016/S1474-4422(09)70211-X
26. Goemans NM, Tulinius M, van den Akker JT, Burm BE, Ekhart PF, Heuvelmans N et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N Engl J Med 2011; 364: 1513–1522. DOI: 10.1056/NEJMoa1011367
27. Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, Anthony K et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 2011; 378: 595–605. DOI: 10.1016/S0140-6736(11)60756-3
28. Mendell JR, Rodino-Klapac LR, Sahenk Z, Roush K, Bird L, Lowes LP et al. Eteplirsen for the treatment of Duchenne muscular dystrophy. Annals of Neurology 2013; 74: 637–647. DOI: 10.1002/ana.23982
29. Bulfield G, Siller WG, Wight PA, Moore KJ. X chromosome-linked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci USA 1984; 81: 1189–1192. DOI: 10.1073/pnas.81.4.1189
30. Deconinck AE, Rafael JA, Skinner JA, Brown SC, Potter AC, Metzinger L et al. Utrophin-dystrophin-deficient mice as a model for Duchenne muscular dystrophy. Cell 1997; 90: 717–727. DOI: 10.1016/S0092-8674(00)80532-2
31. Porter JD, Rafael JA, Ragusa RJ, Brueckner JK, Trickett JI, Davies KE. The sparing of extraocular muscle in dystrophinopathy is lost in mice lacking utrophin and dystrophin. J Cell Sci 1998; 111: 1801–1811.
32. Gregorevic P, Allen JM, Minami E, Blankinship MJ, Haraguchi M, Meuse L et al. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med 2006; 12: 787–789. DOI: 10.1038/nm1439
33. Marshall JL, Holmberg J, Chou E, Ocampo AC, Oh J, Lee J et al. Sarcospan-dependent Akt activation is required for utrophin expression and muscle regeneration. J Cell Bio 2012; 197: 1009–1027. DOI: 10.1083/jcb.201110032
34. Laws N, Hoey A. Progression of kyphosis in mdx mice. J Appl Physiol 2004; 97: 1970–1977. DOI: 10.1152/japplphysiol.01357.2003